Hikal Limited Announces Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2017
August 10, 2017 at 04:04 am EDT
Share
Hikal Limited announced unaudited standalone earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported total revenue of INR 2,682.8 million, profit from operations before other income and interest of INR 183 million, profit from ordinary activities before tax of INR 183 million, net profit after tax of INR 133.2 million or INR 1.60 per basic and diluted share before and after extraordinary items, compared to total revenue of INR 2,268.9 million, profit from operations before other income and interest of INR 135.5 million, profit from ordinary activities before tax of INR 135.5 million, net profit after tax of INR 115.4 million or INR 1.39 per basic and diluted share before and after extraordinary items for the same quarter a year ago. EBITDA was up 13.9% to INR 497.0 million as compared to INR 436.0 million in the corresponding period of the previous year.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
HIKAL LIMITED 
